+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 7 Actively Recruiting clinical trials

E

Actively Recruiting

Researchers are evaluating the safety and effectiveness of efruxifermin EFX in adults with non-cirrhotic nonalcoholic steatohepatitis NASH or metabolic dysfunction-associated steatohepatitis MASH who have moderate to advanced liver fibrosis stage 2 or 3. This Phase 3, multi-center study randomly assigns participants to different treatment groups and compares EFX with a placebo to see its impact on liver health and related clinical outcomes. Participants are divided into two groups one with about 750 subjects having confirmed NASHMASH and fibrosis stage 2 or 3, and another with about 900 subjects with fibrosis stage 3 regardless of their NAFLD activity score. They receive either 28 mg or 50 mg of EFX or a matching placebo through weekly injections under the skin. The study includes a screening period up to 12 weeks, a 52-week treatment phase for the first group, a 96-week phase for the second group, and an extended follow-up period lasting up to around 240 weeks, plus a follow-up visit about a month after the last dose. During the study, participants undergo liver biopsies, blood tests, imaging scans like FibroScan, and assessments of liver fibrosis markers and metabolism-related measures. Researchers monitor changes in liver tissue, liver function tests, cholesterol, blood sugar control, body weight, and safety indicators over time. Even if participants stop the study drug early, they may continue with scheduled assessments to support long-term evaluation of treatment effects and safety throughout the study duration.

Age: 18Years - 80YearsAll GendersPhase 3
359 locations
E

Actively Recruiting

Researchers are studying JADE101, a drug administered by subcutaneous injection, to evaluate its safety and effectiveness in adults with Immunoglobulin A nephropathy IgAN, a kidney condition. This open-label Phase 2 trial aims to better understand how JADE101 works in this patient group and contributes to ongoing clinical knowledge. The study is sponsored by Jade Biosciences, Inc. Participants will receive JADE101 through subcutaneous injections. All participants receive the same treatment without a comparison group. The study will monitor participants from Day 1 through 100 weeks to assess safety and effects on urine protein levels. There is no placebo or blinding in this trial. During the study, participants will attend scheduled visits and undergo laboratory tests to monitor kidney function and protein levels in urine. Researchers will track any treatment-emergent side effects and changes in urine protein creatinine ratio to evaluate the drugs impact. Participants must comply with treatment plans and contraceptive and lifestyle requirements throughout the trial, which lasts approximately 100 weeks.

Age: 18Years - 60YearsAll GendersPhase 2
22 locations
S

Actively Recruiting

Researchers are exploring new treatment options for people with advanced colorectal cancer that has spread or cannot be removed by surgery. This cancer type, affecting the colon or rectum, sometimes involves problems with the bodys DNA repair system called dMMR or a condition called MSI. These issues can cause cancer cells to rely on a protein called Werner helicase to survive. Blocking this protein might help stop cancer growth with less harm to healthy cells. This Phase 2 study evaluates a drug named VVD-133214 that blocks Werner helicase, combined with pembrolizumab, an immunotherapy drug approved to help the immune system attack cancer cells. Participants in this trial will receive oral VVD-133214 along with pembrolizumab given by intravenous infusion every three weeks. The study compares this combination to pembrolizumab alone to find the best dose of VVD-133214 and to assess whether the combination works better. Participants will receive VVD-133214 as long as it remains helpful without causing serious side effects, while pembrolizumab treatment will continue for up to two years. Participants may stop treatment at any time. During the trial, participants will have regular visits for tests, scans, and health check-ups to monitor how their cancer responds and to track any new or worsening medical problems. After stopping treatment, follow-up visits will occur 30 days after the last VVD-133214 dose and 100 days after the last pembrolizumab dose. Long-term follow-up visits will continue every 90 days as long as participants agree to remain in the study. The main outcome measured is the progression-free survival rate at six months, with safety and other response measures also monitored throughout up to about 36 months.

Age: 18Years +All GendersPhase 2
122 locations
P

Actively Recruiting

Researchers are evaluating Ratutrelvir 83-0060, a drug that inhibits the main protease of SARS-CoV-2, along with Paxlovid Nirmatrelvir plus Ritonavir, to understand their safety and effectiveness in adults with mild to moderate COVID-19 who are not hospitalized. This open-label, randomized Phase 2a study aims to determine a safe and effective dose of Ratutrelvir and compare it with standard care, providing important information on how these treatments may help manage COVID-19 symptoms and recovery. Participants will be assigned to receive either Ratutrelvir or Paxlovid alongside standard care. The study is multicenter and open-label, meaning both researchers and participants know which treatment is given. The trial includes an experimental group receiving Ratutrelvir, a comparator group receiving Paxlovid, and a non-randomized group receiving Ratutrelvir. Treatment is given during the study period, and the research team monitors the drugs concentration in the blood to understand how it behaves in the body. During the 28-day study period, participants will be closely monitored for safety based on the occurrence and severity of any adverse events. The team will assess how long it takes for COVID-19 symptoms to improve and recover fully. Blood samples will be collected up to day 11 to analyze drug levels. Participants will undergo symptom evaluations regularly, and their health will be tracked throughout the study to ensure safety and gather data on treatment effects.

Age: 18Years +All GendersPhase 2
15 locations
E

Actively Recruiting

Healthy Volunteer

This research aims to evaluate the effects of an intelligent parent-child bonding intervention on the physical, psychological, and social health of parents with premature infants. The study focuses on parents of babies born before 37 weeks of gestation, addressing challenges such as stress, anxiety, depression, and the impact of mother-child separation. Conducted as a three-year randomized controlled trial, it seeks to improve outcomes related to parent-child relationships and family well-being. Participants are randomly assigned to either receive usual care or the intelligent parent-child bonding intervention. The intervention uses web platforms, software, cloud files, and official communication channels to provide knowledge, skills, and support during hospitalization and up to one month after the premature infant returns home. It includes guidance on care, psychological support, sleep routines, nutrition, and relationship management. The usual care group receives standard hospitalization care and general nursing guidance before discharge. Throughout the study, parents will complete questionnaires and biometric assessments at multiple points before the intervention, two weeks after starting, before hospital discharge, and one month after returning home. Researchers will monitor outcomes including sleep quality, fatigue, stress, anxiety, depression, self-efficacy, parent-child bonding, partner relationships, family resilience, and overall quality of life. The total study duration spans hospitalization through the first month post-discharge, with data analyzed to assess the interventions impact.

Age: 20Years - 80YearsAll GendersPhase Not Applicable
1 location
A

Actively Recruiting

Researchers are studying chronic kidney disease CKD patients who have a higher risk of developing peripheral artery disease PAD, a condition affecting blood flow in the limbs. The study aims to evaluate the effects of a carbon-based oral adsorbent made from activated bamboo charcoal ABC, with or without added probiotics, on vascular and endothelial function, cardiovascular outcomes, and mortality in these patients. They also plan to explore how circulating long noncoding RNA lncRNA and metabolome profiles may predict adverse cardiovascular events and death, while investigating the link between these biomarkers and gut microbiota imbalance in CKD patients with PAD. This is a randomized, open-label trial lasting 6 months, where 120 CKD patients with PAD and 60 healthy controls without PAD will be assigned to receive either the ABC treatment or no treatment. Participants in the treatment groups will take CharXenPlus containing 2g of ABC three times daily for 6 months. Additionally, probiotics will be given once daily during the last 3 months to some subgroups. Samples of urine, stool, and plasma will be collected and stored for further analysis. The trial includes detailed monitoring of kidney function, vascular health, and microbiota changes. Participants will undergo assessments at the start, at 3 months, and at 6 months, including tests such as the six-minute walk test and ankle-brachial index ABI. Researchers will also measure changes in lncRNA, microbiota composition, endothelial progenitor cells, kidney function eGFR, and albuminuria. The study will track cardiovascular, kidney, and limb health outcomes for up to 3 years. Privacy is protected by coded samples and data storage, with the option for participants to allow long-term storage of their samples for future research.

Age: 20Years +All GendersPhase Not Applicable
1 location
S

Actively Recruiting

Researchers are evaluating the effectiveness and safety of a combination of the hexavalent OX40 agonist antibody ordastobart INBRX-106 with the anti-PD-1 antibody pembrolizumab compared to pembrolizumab alone plus placebo in phase 3 as the first-line treatment for patients with recurrent or metastatic HPV-positive Oropharyngeal Squamous Cell Carcinoma HPV OPSCC that expresses PD-L1. This phase 23 seamless randomized controlled trial aims to provide new treatment insights for this patient group. Participants will receive either INBRX-106 plus pembrolizumab or pembrolizumab alone with placebo in phase 3. Both treatments are given by intravenous infusion every three weeks. The study includes two parts phase 2 focusing on objective response rates over one year, and phase 3 assessing progression-free survival and overall survival over up to four years. During the study, participants will be closely monitored through regular assessments including tumor measurements according to RECIST 1.1, clinical evaluations, and safety checks. Researchers will measure outcomes such as response rates, progression-free survival, overall survival, and the incidence of treatment-related side effects. The study also evaluates quality of life and time to chemotherapy. Participants may be followed for up to four years after starting treatment.

Age: 18Years +All GendersPhase 2Phase 3
89 locations